Cargando…

Evidence on port-locking with heparin versus saline in patients with cancer not receiving chemotherapy: A randomized clinical trial

OBJECTIVE: To assess the safety and efficacy of port-locking with heparin every 2 months vs. every 4 months and vs. saline solution every 2 months in patients with cancer not receiving active chemotherapy. The hypothesis stated that locking with heparin at four-month intervals and saline at two-mont...

Descripción completa

Detalles Bibliográficos
Autores principales: Cia-Arriaza, Melania, Cabrera-Jaime, Sandra, Cano-Soria, Rosario, Manzano-Castro, Mireia, Domínguez-Gómez, Margarita, Prieto-Arenas, Dolores M., Benito-Yagüe, Angeles, Sánchez-Martín, Adela, González-Alonso, Cristina, Fernández-Ortega, Paz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345785/
https://www.ncbi.nlm.nih.gov/pubmed/35935884
http://dx.doi.org/10.1016/j.apjon.2022.100085
_version_ 1784761508136222720
author Cia-Arriaza, Melania
Cabrera-Jaime, Sandra
Cano-Soria, Rosario
Manzano-Castro, Mireia
Domínguez-Gómez, Margarita
Prieto-Arenas, Dolores M.
Benito-Yagüe, Angeles
Sánchez-Martín, Adela
González-Alonso, Cristina
Fernández-Ortega, Paz
author_facet Cia-Arriaza, Melania
Cabrera-Jaime, Sandra
Cano-Soria, Rosario
Manzano-Castro, Mireia
Domínguez-Gómez, Margarita
Prieto-Arenas, Dolores M.
Benito-Yagüe, Angeles
Sánchez-Martín, Adela
González-Alonso, Cristina
Fernández-Ortega, Paz
author_sort Cia-Arriaza, Melania
collection PubMed
description OBJECTIVE: To assess the safety and efficacy of port-locking with heparin every 2 months vs. every 4 months and vs. saline solution every 2 months in patients with cancer not receiving active chemotherapy. The hypothesis stated that locking with heparin at four-month intervals and saline at two-month intervals would not increment > 10% of port obstructions. METHODS: Multicentre, phase IV parallel, post-test control group study took place at the two chemotherapy units of oncology hospitals. Included patients with cancer with ports that completed the chemotherapy treatment but still having port maintenance care or blood samples taken up to four months. A sample of 126 patients with cancer in three arms was needed to detect a maximum difference of 10% for bioequivalence on the locking methods. Consecutive cases non-probabilistic sampling and randomized to one of the three groups; group A: received heparin 60 IU/mL every two months (control) vs. group B heparin every four months and vs. saline every two months in group C. Primary variables were the type of locking regimen, port obstruction, and absence of blood return, port-related infection, or venous thrombosis during the study period. Clinical and sociodemographic variables were also collected. RESULTS: A total of 143 patients were randomly assigned; group A, 47 patients with heparin every 2 months, group B, 51 patients with heparin 4 months, and group C, 45 patients with saline every 2 months. All participants presented an adequate blood return and no obstructions, until the month of the 10th, when one participant in the group A receiving was withdrawn due to an absence of blood flow (P ​= ​0.587). CONCLUSIONS: Port locks with heparin every 4 months or saline every 2 months did not show differences in safety maintenance, infection, or thrombosis compared to heparin every 2 months.
format Online
Article
Text
id pubmed-9345785
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93457852022-08-04 Evidence on port-locking with heparin versus saline in patients with cancer not receiving chemotherapy: A randomized clinical trial Cia-Arriaza, Melania Cabrera-Jaime, Sandra Cano-Soria, Rosario Manzano-Castro, Mireia Domínguez-Gómez, Margarita Prieto-Arenas, Dolores M. Benito-Yagüe, Angeles Sánchez-Martín, Adela González-Alonso, Cristina Fernández-Ortega, Paz Asia Pac J Oncol Nurs Original Article OBJECTIVE: To assess the safety and efficacy of port-locking with heparin every 2 months vs. every 4 months and vs. saline solution every 2 months in patients with cancer not receiving active chemotherapy. The hypothesis stated that locking with heparin at four-month intervals and saline at two-month intervals would not increment > 10% of port obstructions. METHODS: Multicentre, phase IV parallel, post-test control group study took place at the two chemotherapy units of oncology hospitals. Included patients with cancer with ports that completed the chemotherapy treatment but still having port maintenance care or blood samples taken up to four months. A sample of 126 patients with cancer in three arms was needed to detect a maximum difference of 10% for bioequivalence on the locking methods. Consecutive cases non-probabilistic sampling and randomized to one of the three groups; group A: received heparin 60 IU/mL every two months (control) vs. group B heparin every four months and vs. saline every two months in group C. Primary variables were the type of locking regimen, port obstruction, and absence of blood return, port-related infection, or venous thrombosis during the study period. Clinical and sociodemographic variables were also collected. RESULTS: A total of 143 patients were randomly assigned; group A, 47 patients with heparin every 2 months, group B, 51 patients with heparin 4 months, and group C, 45 patients with saline every 2 months. All participants presented an adequate blood return and no obstructions, until the month of the 10th, when one participant in the group A receiving was withdrawn due to an absence of blood flow (P ​= ​0.587). CONCLUSIONS: Port locks with heparin every 4 months or saline every 2 months did not show differences in safety maintenance, infection, or thrombosis compared to heparin every 2 months. Elsevier 2022-05-21 /pmc/articles/PMC9345785/ /pubmed/35935884 http://dx.doi.org/10.1016/j.apjon.2022.100085 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Cia-Arriaza, Melania
Cabrera-Jaime, Sandra
Cano-Soria, Rosario
Manzano-Castro, Mireia
Domínguez-Gómez, Margarita
Prieto-Arenas, Dolores M.
Benito-Yagüe, Angeles
Sánchez-Martín, Adela
González-Alonso, Cristina
Fernández-Ortega, Paz
Evidence on port-locking with heparin versus saline in patients with cancer not receiving chemotherapy: A randomized clinical trial
title Evidence on port-locking with heparin versus saline in patients with cancer not receiving chemotherapy: A randomized clinical trial
title_full Evidence on port-locking with heparin versus saline in patients with cancer not receiving chemotherapy: A randomized clinical trial
title_fullStr Evidence on port-locking with heparin versus saline in patients with cancer not receiving chemotherapy: A randomized clinical trial
title_full_unstemmed Evidence on port-locking with heparin versus saline in patients with cancer not receiving chemotherapy: A randomized clinical trial
title_short Evidence on port-locking with heparin versus saline in patients with cancer not receiving chemotherapy: A randomized clinical trial
title_sort evidence on port-locking with heparin versus saline in patients with cancer not receiving chemotherapy: a randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345785/
https://www.ncbi.nlm.nih.gov/pubmed/35935884
http://dx.doi.org/10.1016/j.apjon.2022.100085
work_keys_str_mv AT ciaarriazamelania evidenceonportlockingwithheparinversussalineinpatientswithcancernotreceivingchemotherapyarandomizedclinicaltrial
AT cabrerajaimesandra evidenceonportlockingwithheparinversussalineinpatientswithcancernotreceivingchemotherapyarandomizedclinicaltrial
AT canosoriarosario evidenceonportlockingwithheparinversussalineinpatientswithcancernotreceivingchemotherapyarandomizedclinicaltrial
AT manzanocastromireia evidenceonportlockingwithheparinversussalineinpatientswithcancernotreceivingchemotherapyarandomizedclinicaltrial
AT dominguezgomezmargarita evidenceonportlockingwithheparinversussalineinpatientswithcancernotreceivingchemotherapyarandomizedclinicaltrial
AT prietoarenasdoloresm evidenceonportlockingwithheparinversussalineinpatientswithcancernotreceivingchemotherapyarandomizedclinicaltrial
AT benitoyagueangeles evidenceonportlockingwithheparinversussalineinpatientswithcancernotreceivingchemotherapyarandomizedclinicaltrial
AT sanchezmartinadela evidenceonportlockingwithheparinversussalineinpatientswithcancernotreceivingchemotherapyarandomizedclinicaltrial
AT gonzalezalonsocristina evidenceonportlockingwithheparinversussalineinpatientswithcancernotreceivingchemotherapyarandomizedclinicaltrial
AT fernandezortegapaz evidenceonportlockingwithheparinversussalineinpatientswithcancernotreceivingchemotherapyarandomizedclinicaltrial